AleAnna (NASDAQ:ANNA) & TNF Pharmaceuticals (NASDAQ:TNFA) Head to Head Analysis

AleAnna (NASDAQ:ANNA) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Risk and Volatility

AleAnna has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for AleAnna and TNF Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AleAnna	1	0	0	0	1.00
TNF Pharmaceuticals	1	0	0	0	1.00

Institutional & Insider Ownership

38.1% of AleAnna shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 42.9% of AleAnna shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares AleAnna and TNF Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AleAnna	$1.42 million	334.19	-$12.34 million	$0.04	178.00
TNF Pharmaceuticals	N/A	N/A	-$23.36 million	($231.00)	-0.02

AleAnna has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AleAnna and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AleAnna	-46.01%	-14.90%	-8.74%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Summary

AleAnna beats TNF Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About AleAnna

AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.